About PLPL:
PLPL and its subsidiaries develop highly bioavailable, phytonutrient rich extracts for use in the pharmaceutical, cosmeceutical, wellness, nutraceutical, anti-aging, and food and beverage industries.
PLPL controls every aspect of the process, growing the green tea, avocados, and citrus on its farms in South Africa, to producing the Phytofare™ extracts in-house.
PLPL extracts are being utilized to treat a multitude of diseases and conditions including boosting the immune system, fighting obesity, lowering cholesterol, and aiding in the prevention of cancers, malaria, and many other parasitic and viral infections.
PLPL is also developing and testing Phytofare which is produced from cannabis!
Did you know that just last month the U.S. FDA approved clinical trials for a cannabis based medicine called Epidolex?
This approval truly is a landmark decision and shows that there really could be so much hidden potential locked inside of cannabis and the FDA is ready to accept this.
This is why PLPL thinks its the perfect time to enter into the medical marijuana industry. Check out this recent headline.
Plandai Biotechnology Enters Medical Marijuana Arena With Industry-Changing Technology
PLPL announced this week that it has entered the medical marijuana industry with its new wholly-owned subsidiary, Cannabis Biosciences, Inc., for the purpose of developing and testing a new Phytofare™ botanical extract derived from cannabis. Many different companies have entered the industry, but few of them are biotechnology firms with the potential to use cannabis to better our lives, and even fewer have a technology that can potentially change the industry.
Plandaí executives stated they will preliminarily call the company's cannabis offering "Phytofare™ Phyto-cannabinoid Complex." What should set Plandaí apart from others in the industry is its technology, and the company says this new extract will share a similar extraction process to the other Phytofare™ products and is expected to demonstrate the same high levels of bioavailability and purity.
Even more recently the CEO had this to say.
Plandai Biotechnology's CEO Discusses Direction of Medical Marijuana Subsidiary
Dec 12, 2013
PLPL's subsidiary, Cannabis Biosciences, Inc., will be developing and testing a botanical extract derived from cannabis, and the company's CEO, Roger Duffield, announced it will address neural disorders with its marijuana research. In that announcement Duffield said, "We believe that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, and post-concussion syndrome."
Plandaí, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, expects to use its licensed Phytofare™ and Pheroid™ technologies to produce an FDA approved Phytofare™ cannabinoid complex that can address neural disorders without introducing the psychoactive element of THC to its treatments.
Duffield said, "Our research affirms that damage to the CB1 and CB2 brain receptors contributes to several neuron diseases. Cannabis is rich in neuron-beneficial phytocannabinoids including Δ9-THC; however, Δ9-THC taken in an oral preparation converts in the liver to 11-hydroxy metabolite. This new chemical demonstrates high levels of psycho-activity and is significantly less effective in scavenging free radicals. Essentially, you get the psychotropic aspects of the drug with none of the medicinal benefits."
Unlike other biotechs engaged in marijuana research, Plandaí's extraction and hydrodynamic sheering process combined with its Pheroid™ technology, should allow it to produce an extract that captures and enhances the phytocannabinoids while ideally leaving behind the phychotropic effects.
According to the company, Δ9-THC has similar antioxidant activities as the catechins in green tea by having affinity to the CB1 and CB2 neuron receptors. Plandaí's CEO says, "The science suggests we can produce a highly bioavailable complex that has little if any psychotropic effects and that can deliver a clinical dose to cellular tissues."
Plandaí stated its immediate goal is to undertake the profiling of the Phytofare™ Cannabinoid Complex with in-vitro testing starting within six months. Plandaí anticipates beginning animal trials within twelve months and expects to eventually gain FDA approval for human clinical trials specifically aimed at a number of neural disorders.
"We believe that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, and post-concussion syndrome."
Can you imagine how the market would respond if PLPL was able to come up with a break through in one of these fields durings its cannabis testing?
Please begin you DD on PLPL today.
Good luck!
-The Professor
